J&J buys Aragon’s prostate cancer arm


Hormonally-driven cancer drug discovery specialist Aragon Pharmaceuticals has been bought by Johnson & Johnson. The deal covers Aragon’s androgen receptor antagonist programme, including an advanced drug candidate for prostate cancer.

Androgen has spun out the rest of the company to form Seragon Pharmaceuticals, which will develop breast cancer drugs that work by degrading oestrogen receptors.

J&J paid $650 million (£417 million) up front, and will pay up to $350 million more if various milestones are reached. The androgen receptor antagonist programme will be managed by J&J’s subsidiary Janssen.


Related Content

Genentech to buy breast cancer specialist Seragon

2 July 2014 Business

news image

$1.7bn deal for hormone receptor-destroying drug pipeline

Riding new waves

6 January 2015 Business

news image

Pharmaceutical industry roundup of 2014

Most Read

Hydrogel with a basic instinct for drug delivery

15 April 2015 Research

news image

Gel that releases naproxen in alkaline surroundings is promising step toward relieving drug’s side effects

Early Earth collision could clear up two geological mysteries

16 April 2015 Research

news image

Smash-up with Mercury-like body could have ignited nuclear dynamo at Earth's centre and explain isotope discrepancy

Most Commented

Membrane-less electrolyser set to disrupt water splitting

20 April 2015 Research

news image

Device that exploits fluid mechanic forces has potential to significantly cut cost of hydrogen production

Oh, the humanities!

20 April 2015 The Crucible

news image

Science and the arts are equally essential to society, says Philip Ball. Don’t divide them by their differences